Guar gum 5g granules sachets sugar free
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Guar gum
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Guar gum
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 18 · Randomised trials: 1 · 2005–2026
Showing the 50 most relevant studies, sorted by most relevant.
Nandkishore Thombare, U. Jha, S. Mishra, et al.
International journal of biological macromolecules, 2016
G. Sharma, Shweta Sharma, Amit Kumar, et al.
Carbohydrate polymers, 2018
Anna Evelin Juhász, Tímea Klaudia Kara, Éva Csajbókné Csobod, et al.
Nutrients, 2026
- Trigonella
- Galactans
- Mannans
Background: Guar (Cyamopsis tetragonoloba), locust bean (Ceratonia siliqua), fenugreek (Trigonella foenum-graecum), and tara (Caesalpinia spinosa) are plant-derived materials that contain galactomannans as their major polysaccharide component. Galactomannans are soluble, highly viscous, and fermentable dietary fibers widely used in the food, pharmaceutical, and cosmetic industries because of their favorable technological properties. Methods: We performed our systematic search on 16 April 2026, in MEDLINE (via PubMed), Scopus, and the Cochrane Central Register of Controlled Trials (CENTRAL), without language restrictions. Eligible randomized controlled trials compared the effects of guar gum, locust bean gum, and fenugreek on glycemic parameters, lipid profile, and body weight-related outcomes in healthy adults or patients with metabolic disorders. Results: A total of 50 randomized controlled trials were included in the analysis. Of these, 27 investigated guar gum, 20 fenugreek (12 seed powder, 7 seed extract, 1 leaf extract), two mixed galactomannan preparations, and one locust bean gum intervention. Considerable heterogeneity was observed across studies regarding participant characteristics, intervention doses, and treatment duration. Nevertheless, fenugreek-derived preparations consistently improved glycemic outcomes. In contrast, guar gum demonstrated more consistent effects on lipid parameters. Effects on body weight and body mass index were less consistent across studies. Conclusions: Our findings suggest that the metabolic effects of galactomannans are source-dependent, with fenugreek-based interventions appearing to have greater potential for improving glycemic outcomes, while guar gum may be more effective in improving lipid parameters. Since these fibers can be easily consumed in the form of dietary supplements, it is worth considering their regular, daily intake. The protocol was prospectively registered in the PROSPERO database (CRD420261368159).
Abstract licence: CC BY 4.0
A. George, P. Shah, P. Shrivastav
European Polymer Journal, 2019
Sima Tahmouzi, Heidar Meftahizadeh, Saba Eyshi, et al.
Food Science & Nutrition, 2023
Nandkishore Thombare, S. Mishra, M. Z. Siddiqui, et al.
Carbohydrate polymers, 2018
Jiawei Wang, Yuan Huang, Binbin Liu, et al.
Energy Storage Materials, 2021
L. S. Kuck, C. Noreña
Food chemistry, 2016
A. Hasan, M. Abdel-raouf
Egyptian Journal of Petroleum, 2018
Karolin Weitkunat, Christin Stuhlmann, Anna Postel, et al.
Scientific Reports, 2017
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Investigational
Major interactions
None known
Half-life
Not available
Mechanism
Not available
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 605 interactions
ATC A10BX01
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Guar gum
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72